 prolong surviv patient beta-thalassemia major deferoxamin surviv patient beta-thalassemia major manag hypertransfus chelat deferoxamin longev kaplan-mei product-limit method group patient low-transfus regimen pretransfus level gm/dl chelat median age surviv year year group subject hypertransfus pretransfus level gm/dl chelat deferoxamin mg/kg day patient hypertransfus deferoxamin data ratio total milligram transfusion iron cumul gram deferoxamin patient total iron burden gm/kg ratio patient poor complianc chelat late start therapi inabl enough deferoxamin death death arrhythmia therapi cardiac failur iron-load survivor ratio arrhythmia cardiac failur treatment deferoxamin amount proport burden delay cardiac complic improv longev